📊 CYDY Key Takeaways
Investment Thesis
CytoDyn exhibits severe financial distress with negative stockholders' equity of -$119.7M, indicating the company is technically insolvent. The company has zero revenue, massive operating losses of -$26.6M, and is burning cash at -$6.8M annually with only $5.0M in cash reserves. The balance sheet shows liabilities exceeding assets by $119.7M, creating an unsustainable capital structure.
CYDY Strengths
- Slight improvement in net loss year-over-year (loss narrowed by 65.6%, though still deeply negative)
- Minimal capital expenditure ($30K) suggests company has eliminated discretionary spending
- Still maintains $5.0M in cash reserves providing limited runway
CYDY Risks
- Negative stockholders' equity of -$119.7M indicates technical insolvency and high bankruptcy risk
- Zero revenue generation with no apparent path to commercialization
- Massive cash burn of -$6.8M annually against only $5.0M in cash reserves (less than 1 year of runway)
- Current ratio of 0.10x indicates severe liquidity crisis and inability to meet short-term obligations
- Operating losses of -$26.6M with no revenue offsetting expenses
- Long-term debt of $42.2M on nearly-worthless asset base with negative equity
Key Metrics to Watch
- Cash burn rate and remaining months of cash runway
- Whether company achieves any revenue or FDA approval for pipeline assets
- Debt restructuring or refinancing announcements
- Additional equity dilution from capital raises needed for survival
CYDY Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CYDY Profitability Ratios
CYDY vs Healthcare Sector
How CytoDyn Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CYDY Balance Sheet & Liquidity
CYDY 5-Year Financial Trend
5-Year Trend Summary: CytoDyn Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.05 indicates the company is currently unprofitable.
CYDY Growth Metrics (YoY)
CYDY Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | $266.0K | -$13.7M | $-0.02 |
| Q2 2023 | $225.0K | -$21.0M | $-0.03 |
| Q1 2023 | $41.0K | -$21.0M | $-0.03 |
| Q3 2021 | N/A | -$30.8M | $-0.05 |
| Q2 2021 | N/A | -$30.8M | $-0.05 |
| Q1 2021 | N/A | -$30.8M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CYDY Capital Allocation
CYDY SEC Filings
Access official SEC EDGAR filings for CytoDyn Inc. (CIK: 0001175680)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CYDY
What is the AI rating for CYDY?
CytoDyn Inc. (CYDY) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CYDY's key strengths?
Slight improvement in net loss year-over-year (loss narrowed by 65.6%, though still deeply negative). Minimal capital expenditure ($30K) suggests company has eliminated discretionary spending.
What are the risks of investing in CYDY?
Negative stockholders' equity of -$119.7M indicates technical insolvency and high bankruptcy risk. Zero revenue generation with no apparent path to commercialization.
What is CYDY's revenue and growth?
CytoDyn Inc. reported revenue of $0.0.
Does CYDY pay dividends?
CytoDyn Inc. does not currently pay dividends.
Where can I find CYDY SEC filings?
Official SEC filings for CytoDyn Inc. (CIK: 0001175680) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CYDY's EPS?
CytoDyn Inc. has a diluted EPS of $-0.02.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.